Aspen Park Pharmaceuticals

Aspen Park Pharmaceuticals Overview

Founded 2014
Founded
Status Acquired/​Merged
Employees 2
Employees
Latest Deal Type M&A
Financing Rounds 3

Aspen Park Pharmaceuticals General Information

Description

Developer of novel therapies for premature ejaculation in men. The company focuses on the development and commercialization of novel therapies for men's health diseases and conditions, including male secondary hypogonadism, prostate cancer, and sexual dysfunction.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Therapeutic Devices
Other Industries
Managed Care
Clinics/Outpatient Services
Acquirer
Primary Office
  • 944 Park Avenue
  • New York, NY 10028
  • United States

Aspen Park Pharmaceuticals Timeline

20152016
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aspen Park Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aspen Park Pharmaceuticals‘s full profile, request access.

Request a free trial

Aspen Park Pharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
Harry Fisch Co-Founder, Chairman & Chief Scientific Officer
Mitchell Steiner Ph.D Co-Founder, President, Managing Director & Chief Executive Officer

Aspen Park Pharmaceuticals Board Members (2)

Name Representing Role Since
00000 000000000 Self Board Member 000 0000
0000000 00000 Self Board Member 000 0000